Baseline serum leptin predicts peritoneal dialysis adequacy: a single-center prospective, longitudinal study

  • N. Stepanova State Institute «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine»
  • O. Burdeyna State Institute «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine»
  • V. Driianska State Institute «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine»
  • O. Ablogina Dialysis Center "Nadiya"
Keywords: peritoneal dialysis, serum leptin, adequacy


Hyperleptinemia is often observed in peritoneal dialysis (PD) patients. But, there are few studies on the relationship between blood leptin level and PD survival, and, some of them contradict each other.

The present study aimed to investigate the impact of PD initiation on the serum leptin concentrations and its association with PD adequacy.

Method. A total of 23 patients with end-stage renal disease (ESRD), who started the treatment with continuous ambulatory peritoneal dialysis (CAPD), were included in this prospective single-center observational longitudinal study. Among the patients, there were 15 men and 8 women; the average age of the patient population was 52.4 ± 12.3 years. The treatment with CAPD was performed using Dianeal PD 4 with glucose concentration of 1.36% and 2.27%. The patients were screened before PD initiation and after 3- and 12- month PD treatment. Leptin levels were determined in all patients using ELISA-method.

Results. The median serum leptin concentration at study entry was 10.6 [5.6-21.9] ng/mL. Leptin level and its dynamics during the year after PD treatment initiation were dependent on body mass index (BMI). The overweight or obese patients had ever-increasing leptin levels after 3- and  12- month PD treatment. Whereas in the PD patients with normal weight, we observed a significant decrease of leptin levels after 12-month PD treatment. Serum leptin concentration in the women was significantly higher compared with the men (46.4 [1.1-95] vs 9.8 [3.2-14.5] ng/mL; p = 0.02). Blood cholesterol levels had a positive correlation with serum leptin concentrations after 3- and 12- month PD treatment: r = 0.53, p = 0.01 and r = 0.56, p = 0.008, respectively. However, we did not find a statistically significant association of leptin with PD adequacy parameters after 3- and 12- month PD treatment of the patients. 

In the Cox proportional hazard model adjusted for gender, serum leptin level demonstrated itself as the effective factor in PD adequacy survival: HR 5.3 (95% CI 1.7; 16.3).

PD adequacy survival was better in the patients with leptin concentrations above the median (≥10.6 ng/mL) compared with the patients who had serum leptin levels below the median (log rank test, χ2 = 8.2; p = 0.0042).

Conclusions. Our study have demonstrated markedly elevated serum leptin  level in the overweight PD patients and its strong decrease during 12 months in the patients with normal weight. Low serum leptin level before PD initiation is associated with inadequate PD.


Download data is not yet available.


Wong B, Ravani P, Oliver MJ, Holroyd-Leduc J, Venturato L, Garg AX, Quinn RR.Comparison of Patient Survival Between Hemodialysis and Peritoneal Dialysis Among Patients Eligible for Both Modalities. Am J Kidney Dis. 2018;71(3):344-351. doi: 10.1053/j.ajkd.2017.08.028.

Velloso MS, Otoni A, de Paula Sabino A, de Castro WV, Pinto SW, Marinho MA, et al. Peritoneal dialysis and inflammation. Clin Chim Acta. 2014; 20;430:109-14. doi: 10.1016/j.cca.2013.12.003.

Cho Y, Hawley CM, Johnson DW. Clinical causes of inflammation in peritoneal dialysis patients. Int J Nephrol. 2014;2014:909373. doi:10.1155/2014/909373.

Briley LP, Szczech LA. Leptin and renal disease. Semin Dial. 2006;19(1):54-9. doi: 10.1111/j.1525-139X.2006.00119.x

Fang TC, Lee CJ, Wang CH, et al. Fasting serum leptin level correlates with mid-arm fat area in peritoneal dialysis patients. Ther Apher Dial. 2010;14:583–588. doi: 10.1111/j.1744-9987.2010.00847.x.

Díez JJ, Bossola M, Fernández-Reyes MJ, Di Stasio E, Tazza L, Luciani G, et al. Relationship between leptin and all-cause and cardiovascular mortality in chronic hemodialysis patients. Nefrologia. 2011;31:206–212. doi: 10.3265/Nefrologia.pre2010.Dec.10629.

Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin. 2018 Jul;39(7):1176-1188. doi: 10.1038/aps.2018.40.

Mills KT, Hamm LL, Alper AB, et al. Circulating adipocytokines and chronic kidney disease. PLoS One. 2013;8(10):e76902. Published 2013 Oct 7. doi:10.1371/journal.pone.0076902

Golembiewska E, Safranow K, Ciechanowski K, Bober J, Bogacka A, Stepniewska J. Adipokines and parameters of peritoneal membrane transport in newly started peritoneal dialysis patients. Acta Biochim Pol. 2013;60(4):617-21.

Tsai JP, Tsai CC, Liu HM, et al. Hyperleptinaemia positively correlated with metabolic syndrome in hemodialysis patients. Eur J Intern Med. 2011;22:e105–e109. doi: 10.1016/j.ejim.2011.02.015.

Pecoits-Filho R, Nordfors L, Heimburger O, Lindholm B, Anderstam B, Marchiewska A et al. Soluble leptin receptors and serum leptin in end-stage renal disease. relationship with inflammation and body composition. Eur J Clin Invest 2002;32:811–7.

Malyszko J, Malyszko JS, Mysliwiec M. Visfatin and endothelial function in dialyzed patients. Nephrology (Carlton). 2010;15(2):190-6. doi: 10.1111/j.1440-1797.2009.01180.x.

Nolph KD, Moore HL, Twardowski ZJ, Khanna R, Prowant B, Meyer M, Ponferrada L: Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis. ASAIO J. 1992;38:M139-42.

Hung AM, Sundell MB, Egbert P, et al. A Comparison of Novel and Commonly-Used Indices of Insulin Sensitivity in African American Chronic Hemodialysis Patients. Clin J Am Soc Nephrol. 2011;6(4):767-774. doi:10.2215/CJN.08070910.

Scholze  A, Rattensperger  D, Zidek  W, Tepel M. Low Serum Leptin Predicts Mortality in Patients with Chronic Kidney Disease Stage 5. Obesity.2007;15(6):1617-22. doi.: 10.1038/oby.2007.191

Momeni A, Seirafian S. Relationship Between Serum Leptin Level and Peritonitis in CAPD Patients. Nephro-Urol Mon. 2011;3(4):272-275.

Dagogo-Jack S, Ovalle F, Landt M, Gearing B, Coyne DW. Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1998;18:134-40.

Jiang S, Song K, Feng S, Shi YB. Association between serum leptin levels and peritoneal dialysis: A meta-analysis. Exp Ther Med. 2015;10(1):300-308. doi: 10.3892/etm.2015.2441

Stenvinkel P, Lindholm B, Lönnqvist F, Katzarski K, Heimbürger O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. Am Soc Nephrol. 2000;11(7):1303-9.

Teta D, Maillard M, Halabi G, Burnier M. The leptin/adiponectin ratio: potential implications for peritoneal dialysis. Kidney Int Suppl. 2008;(108):S112-8. doi: 10.1038/

Kim DJ, Oh DJ, Kim B, Lim YH, Kang WH, Lee BH, Lee SK, Huh W, et al The effect of continuous ambulatory peritoneal dialysis on change in serum leptin. Perit Dial Int. 1999;19(2):S172-5.

Park J, Ahmadi SF, Streja E, et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis. 2013;56(4):415-25. doi: 10.1016/j.pcad.2013.10.005

Kalantar-Zadeh K, Rhee CM, Chou J, et al. The Obesity Paradox in Kidney Disease: How to Reconcile it with Obesity Management. Kidney Int Rep. 2017;2(2):271-281. doi: 10.1016/j.ekir.2017.01.009

Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ. Body size and outcomes on peritoneal dialysis in the United States. Kidney international. 2003;64(5):1838-44. doi: 10.1046/j.1523-1755.2003.00287.

Beltowski, J., Wojcicka, G., Borkowska, E. Human leptin stimulates systemic nitric oxide production in the rat. Obes Res. 2002;10:939-46. doi.: 10.1038/oby.2002.128

How to Cite
Stepanova, N., Burdeyna, O., Driianska, V., & Ablogina, O. (2018). Baseline serum leptin predicts peritoneal dialysis adequacy: a single-center prospective, longitudinal study. Ukrainian Journal of Nephrology and Dialysis, (4(60), 3-10.